Table 1.
Summary of quadrivalent HPV vaccine efficacy assumptions.
| Vaccine efficacy assumptions | HPV 16 | HPV 18 | HPV 6 | HPV 11 |
|---|---|---|---|---|
| Cervical cancer | ||||
| Prevention of cervical HPV infections: | ||||
| - Malea | 0.411 | 0.621 | ||
| - Femaleb | 0.760 | 0.963 | ||
| Prevention of HPV persistent infections | 0.988 | 0.984 | ||
| Protection against HPV-related CIN | 0.979 | 1 | ||
| Vaginal and vulvar cancers | ||||
| Prevention of VaIN/VIN infections: | ||||
| - Malea | 0.411 | 0.621 | ||
| - Femaleb | 0.760 | 0.963 | ||
| Prevention of persistent VaIN/VIN | 0.988 | 0.984 | ||
| Protection against HPV-related VaIN/VIN | 1 | 1 | ||
| Anal cancers | ||||
| Prevention of anal infections | ||||
| - Malea | 0.411 | 0.621 | ||
| - Femaleb | 0.760 | 0.963 | ||
| Protection against persistent anal infections | ||||
| - Malea | 0.787 | 0.960 | ||
| - Femaleb | 0.988 | 0.984 | ||
| Protection against HPV-related AIN neoplasia | 0 | 0 | ||
| Genital warts | ||||
| Vaccine efficacy against HPV 6/11 infection | ||||
| - Female | 0.761 | 0.761 | ||
| - Males | 0.490 | 0.570 | ||
| Protection of the vaccine against HPV 6/11-related genital warts | ||||
| - Female | 0.989 | 1 | ||
| - Male | 0.843 | 0.909 | ||
| Protection against HPV 6/11-related CIN 1 | 1 | 1 | ||
AIN: Anal Intraepithelial Neoplasia; CIN: Cervical Intraepithelial Neoplasia; VaIN: Vaginal Intraepithelial Neoplasia; VIN: Vulvar Intraepithelial Neoplasia.
a
Preventing male genital infections through male vaccination is assumed to prevent transmission of genital infections to females.
b
Preventing female genital infections through vaccination is assumed to prevent transmission of genital infections to males.